Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Cannabis use does not appear to undermine the effectiveness of evidence-based PTSD therapies, even in patients managing multiple substance-related challenges.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by providing evidence on whether trauma-focused PTSD treatments maintain efficacy in patients with concurrent cannabis use and comorbid substance use disorders, populations historically excluded from or underrepresented in RCTs. The findings directly inform treatment selection and expected outcomes for the substantial proportion of PTSD patients who use cannabis, enabling clinicians to make evidence-based decisions about pursuing standard trauma-focused interventions versus alternative approaches in this high-need population. Understanding treatment response in cannabis users with co-occurring PTSD and SUDs has direct implications for treatment planning, patient counseling, and resource allocation in integrated dual-diagnosis care settings.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis adds important nuance to a clinically common scenario, examining whether trauma-focused treatments retain efficacy in patients with co-occurring PTSD, cannabis use, and other substance use disorders. The pooled analysis from Project Harmony’s dataset provides valuable real-world evidence, though we should note that the specific subset examined comprised only four RCTs and represents patients willing to enroll in controlled trials, which may not fully capture the complexity of treatment-seeking populations in routine practice. Cannabis use patterns, frequency, and dependence severity were likely heterogeneous across studies, and the analysis doesn’t clarify whether cannabis was actively used during treatment or whether its role as self-medication versus independent contributor to outcomes was disentangled from concurrent alcohol or opioid use. Despite these limitations, the findings matter clinically: if trauma-focused treatments (such as prolonged exposure or cognitive processing therapy) demonstrate comparable effectiveness regardless of cannabis use status, this supports offering evidence-based PTSD care without automatically deprioritizing or delaying
| |